PSMA PET/CT Detection of Chondromyxoid Fibroma-Reference-Cited by-同舟云学术

PSMA PET/CT Detection of Chondromyxoid Fibroma

Published:2023-04-05 Issue:6 Volume:48 Page:545-546
ISSN:1536-0229
Container-title:Clinical Nuclear Medicine
language:en
Short-container-title:Clin Nucl Med

Author:

Jang Albert¹,Caputo Sydney A.²,Hawkins Madeline E.³,Talbert Joshua E.⁴,Sartor Oliver³

Affiliation:

1. Deming Department of Medicine, Tulane University School of Medicine

2. Tulane University School of Medicine

3. Tulane Cancer Center

4. Department of Radiology, Tulane University School of Medicine, New Orleans, LA.

Abstract

Abstract A 61-year-old man underwent a piflufolastat 18F prostate-specific membrane antigen (PSMA) PET/CT scan due to a rising prostate-specific antigen level. The scan noted a focal cortical erosion on the CT scan in the right anterolateral tibia, and the PET showed an SUVmax of 4.08. A biopsy of this lesion revealed a chondromyxoid fibroma. This rare case of a PSMA PET-positive chondromyxoid fibroma illustrates the importance of radiologists and oncologists not to assume an isolated bone lesion on a PSMA PET/CT scan as a bone metastasis from prostate cancer.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Radiology, Nuclear Medicine and imaging,General Medicine

Reference9 articles.

1. Correlation of neoplasms with incidence and localization of skeletal metastases: an analysis of 1,355 diphosphonate bone scans;J Nucl Med,1975

2. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients;Hum Pathol,2000

3. Pattern and distribution of bone metastases in common malignant tumors;Nucl Med Rev Cent East Eur,2013

4. Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings;Cancer Imaging,2020

5. Bone uptake in prostate cancer patients: diagnostic performances of PSMA-RADS v1.0, clinical, biological, and 68 Ga-PSMA-11 PET features to predict metastasis after biochemical recurrence;Clin Nucl Med,2022